Cargando…

Conflict of Interest Disclosures

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Conflict of Interest Disclosures
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149630/ https://www.ncbi.nlm.nih.gov/pubmed/35616076 http://dx.doi.org/10.1177/21925682221100975

Ejemplares similares

Conflict of Interest Disclosures
Publicado: (2017)

Conflict of Interest Disclosures
Publicado: (2018)

Conflict of Interest Disclosures
Publicado: (2019)

Conflict of Interest Disclosures
Publicado: (2021)

Conflict of Interest Disclosures
Publicado: (2023)

Disclosures
Publicado: (2016)

Beyond Money: Conscientious Objection in Medicine as a Conflict of Interests
por: Giubilini, Alberto, et al.
Publicado: (2020)

Conflicts of Interest Result From Relationships But Are Not Resolved by Preventing Relationships
por: Petrini, Carlo, et al.
Publicado: (2021)

Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation
por: Marks, Jonathan H.
Publicado: (2020)

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
por: Kong, Chao, et al.
Publicado: (2023)

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
por: Toader, Dorin, et al.
Publicado: (2023)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

EDITOR'S CHOICE: Competition on the range: science vs. perception in a bison–cattle conflict in the western USA
por: Ranglack, Dustin H., et al.
Publicado: (2015)

Clarification of Conflict of Interest Disclosure
Publicado: (2022)

Errors in Conflict of Interest Disclosures
Publicado: (2022)

Incomplete Conflict of Interest Disclosures
Publicado: (2022)

Incomplete Conflict of Interest Disclosures
Publicado: (2019)

Error in Conflict of Interest Disclosures
Publicado: (2020)

Error in Conflict of Interest Disclosures
Publicado: (2023)

Sound-induced analgesia cannot always be observed in adult mice
por: Chen, Qi-Yu, et al.
Publicado: (2023)

Errors in the Conflict of Interest Disclosures Statement
Publicado: (2022)

Errors in Text and Conflict of Interest Disclosures
Publicado: (2019)

Disclosure of conflict of interest in scientific publications
por: Sharma, Suhasini
Publicado: (2020)

Does Conflict of Interest Disclosure Worsen Bias?
Publicado: (2012)

Disclosure of conflicts of interest and credibility for the medical profession
por: Braillon, Alain, et al.
Publicado: (2015)

Errors in Byline, Affiliations, and Conflict of Interest Disclosures
Publicado: (2020)

Perceptions of Conflict of Interest Disclosures among Peer Reviewers
por: Lippert, Suzanne, et al.
Publicado: (2011)

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
por: Roulston, Anne, et al.
Publicado: (2022)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
por: Zimmermann, Astrid, et al.
Publicado: (2022)

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
por: Darvishi, Emad, et al.
Publicado: (2022)

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
por: Rigby, Michael, et al.
Publicado: (2022)

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
por: Deng, Jiaojiao, et al.
Publicado: (2021)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
por: Smith, Bryan D., et al.
Publicado: (2021)

Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
por: Li, Xiaofan, et al.
Publicado: (2023)

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
por: Rossmueller, Gregor, et al.
Publicado: (2023)

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
por: Mazahreh, Rebecca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bbghvfek4m4k721ngolt0jt8lc